Atlas Trials

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Clinical trial NCT02924376 · COMPLETED

Trial details

NCT number
NCT02924376
Sponsor
Incyte Corporation
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Cholangiocarcinoma
Start date
2017-01-16
Primary completion
2022-02-01
Enrollment
147

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.